VEGFB is altered in 0.51% of non-small cell lung carcinoma patients [3].

VEGFB is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain VEGFB status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

VEGFB is altered in 0.56% of malignant solid tumor patients [3].

VEGFB is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains VEGFB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

VEGFB is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].